Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Neogambogic acid

🥰Excellent
Catalog No. T5724Cas No. 93772-31-7
Alias neo-gambogic acid

Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.

Neogambogic acid

Neogambogic acid

🥰Excellent
Purity: 99.38%
Catalog No. T5724Alias neo-gambogic acidCas No. 93772-31-7
Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
Pack SizePriceAvailabilityQuantity
1 mg$46In Stock
5 mg$98In Stock
10 mg$148In Stock
25 mg$249In Stock
50 mg$369In Stock
100 mg$548In Stock
Bulk & Custom
Add to Cart
Questions
View More

Related Compound Libraries of "Neogambogic acid"

Select Batch
Purity:99.38%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.
In vitro
Neo-gambogic acid(NGA) significantly reduced the proliferation of MCF-7 cells in a dose-dependent manner. NGA could increase the expression of the apoptosis-related proteins FasL, caspase-3, caspase-8, caspase-9, and Bax and decrease the expression of anti-apoptotic protein Bcl-2 accompanied by the mitochondrial transmembrane damage. The antiproliferative effect of NGA on MCF-7 cells is due to the G(0)/G(1) arrest, increased apoptosis and activation of Fas/FasL and cytochrome C pathway[1].
In vivo
Neo-gambogic acid(NGA) dose of ≤0.4 μg/ml had no significant effect on the proliferation of mouse BMMs in vitro (P>0.05);?concentrations of between 0.1-0.4 μg/ml significantly inhibited RANKL-induced osteoclastogenesis (P<0.01) in a dose-dependent manner.?Compared with the control group, NGA significantly reduced RANKL-induced bone resorption in vitro (P <0.01), and downregulated the expression of osteoclast-related mRNAs of TRAP, CTR, CTSK, and NFATc1.?NGA suppressed the activation of JNK but not the p38 signaling pathway and significantly reduced NF-κB p65 phosphorylation and the nuclear transport of NF-κB molecules, which inhibited NFATc1 expression.?CONCLUSIONS NGA suppressed RANKL-induced osteoclastogenesis by inhibiting the JNK and NF-κB pathways in mouse BMMs in vitro and reduced osteoclastic bone resorption[2].
Cell Research
MCF-7 cells (5* 10^4 ) were seeded into 96-well plates.Four hours later, 10 ul NGA in DMSO was added into the wells at various concentrations (0.5-24 ug/ml) and 0.1% DMSO was set as a negative control.?After 72 h, 50 ul MTT was added and cells were incubated for another 4 h. Then, media was removed and 150 ul DMSO was added and the plates were placed on a shaking table at 150 rpm for 10 min. Optical density (OD) was measured at 490 nm.?The experiment was repeated thrice and the rate of cell inhibition was calculated using the following formula: inhibition rate [1-(OD test/ OD negative control)]*100%[1].
Animal Research
Primary mouse BMMs were cultured with increasing concentrations of NGA.?Real-time polymerase chain reaction was used to study the expression of mRNAs corresponding to gene products specific to receptor activator of NF-κB ligand (RANKL)-induced osteoclast differentiation, including tartrate-resistant acid phosphatase (TRAP), calcitonin receptor (CTR), cathepsin K (CTSK), and nuclear factor of activated T cells c1 (NFATc1).?A cell counting kit-8 assay was used to evaluate cell proliferation.?Western blotting and confocal immunofluorescence microscopy were used to investigate the signaling pathways.?A bone resorption model was used to quantify bone resorption[2].
Aliasneo-gambogic acid
Chemical Properties
Molecular Weight646.77
FormulaC38H46O9
Cas No.93772-31-7
SmilesC(/C=C(\C(O)=O)/C)[C@@]12[C@]34C(C(=O)C=5C(O3)=C(CC=C(C)C)C6=C(C5O)C(O)C[C@](CCC=C(C)C)(C)O6)=CC(C1=O)(C[C@]4(C(C)(C)O2)[H])[H]
Relative Density.1.32 g/cm3
Storage & Solubility Information
Storagekeep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 6.47 mg/mL (10 mM)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM1.5461 mL7.7307 mL15.4614 mL77.3072 mL
5 mM0.3092 mL1.5461 mL3.0923 mL15.4614 mL
10 mM0.1546 mL0.7731 mL1.5461 mL7.7307 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Neogambogic acid | purchase Neogambogic acid | Neogambogic acid cost | order Neogambogic acid | Neogambogic acid chemical structure | Neogambogic acid in vivo | Neogambogic acid in vitro | Neogambogic acid formula | Neogambogic acid molecular weight